Payment overview · 2025
General Payments
$2,541.74
152 reported records · 39 companies
Healthcare provider profile · identity verified
Megan Collett, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · LEXINGTON, KY · NPI 1134580145
Verified facts
What the public records show
CMS Open Payments records show Megan Collett, APRN received $2,541.74 in general payments during 2025 across 152 reported records.
ABBVIE INC. accounted for 17.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 46 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Horizant, Ingrezza, Nuplazid, Nurtec Odt, Qulipta, Rexulti, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Ubrelvy by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Nuplazid by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported HORIZANT as an associated drug or biological on 2733 records involving 1696 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Horizant by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REYVOW as an associated drug or biological on 378 records involving 290 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Reyvow by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ingrezza by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $446.01 | 17.6% | 40 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $190.26 | 7.5% | 24 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $167.85 | 6.6% | 5 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $158.58 | 6.2% | 7 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $136.70 | 5.4% | 4 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $104.60 | 4.1% | 4 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $88.25 | 3.5% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $85.69 | 3.4% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $82.22 | 3.2% | 4 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $78.20 | 3.1% | 4 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $78.04 | 3.1% | 4 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $75.90 | 3.0% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $61.05 | 2.4% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $59.93 | 2.4% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $57.63 | 2.3% | 3 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $56.68 | 2.2% | 2 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $43.36 | 1.7% | 2 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $42.16 | 1.7% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $41.98 | 1.6% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $41.69 | 1.6% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $40.64 | 1.6% | 2 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $35.25 | 1.4% | 2 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$34.01 | 1.3% | 1 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $33.56 | 1.3% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $29.87 | 1.2% | 2 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $25.93 | 1.0% | 1 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $21.96 | 0.9% | 1 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $21.44 | 0.8% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $21.43 | 0.8% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $21.42 | 0.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.18 | 0.8% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$20.07 | 0.8% | 1 | 2025 |
| Cala Health, Inc. | Unresolved — no canonical attribution shown | $19.77 | 0.8% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.28 | 0.8% | 1 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.95 | 0.7% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.57 | 0.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.15 | 0.6% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $15.61 | 0.6% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $13.87 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,483.25 | 151 |
| Education | $58.49 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $240.44 | 18 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $228.30 | 22 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $190.26 | 24 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $190.26 | 24 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $172.67 | 21 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $158.58 | 7 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $104.60 | 4 | 2025 |
Source payment records
|
|||||
| Mavenclad Normalized: mavenclad |
Drug | EMD Serono, Inc. | $95.88 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $88.25 | 5 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $85.69 | 4 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $82.22 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $78.21 | 3 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $78.20 | 4 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $78.04 | 4 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $64.57 | 3 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $59.93 | 3 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $56.85 | 3 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $44.65 | 2 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $43.36 | 2 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $42.16 | 2 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $41.69 | 2 | 2025 |
Source payment records
|
|||||
| CDS - MCT/CEM Monitoring Normalized: cds mct cem monitoring |
Device | Boston Scientific Corporation | $40.41 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $37.46 | 2 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $35.25 | 2 | 2025 |
Source payment records
|
|||||
| Dysport Normalized: dysport |
Drug | Ipsen Biopharmaceuticals, Inc | $33.56 | 2 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $32.90 | 1 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $25.93 | 1 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $25.47 | 1 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $24.60 | 1 | 2025 |
Source payment records
|
|||||
| NUEDEXTA Normalized: nuedexta |
Drug | Otsuka America Pharmaceutical, Inc. | $23.59 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | Octapharma USA, Inc. | $21.96 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $21.44 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $21.43 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $21.42 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| Cala kIQ Normalized: cala kiq |
Device | Cala Health, Inc. | $19.77 | 1 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $19.28 | 1 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $17.95 | 2 | 2025 |
Source payment records
|
|||||
| General - DBS Normalized: general dbs |
Device | Boston Scientific Corporation | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $16.57 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $16.38 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $16.04 | 1 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $13.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| HORIZANT horizant |
2025 | Horizant | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 51 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 150 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
150 | 33 |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | HORIZANT open payments reported associated product |
CMS Open Payments — General Payments 2733 supporting records · 1696 recipient NPIs · example record 1242666828 |
Horizant · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | REYVOW open payments reported associated product |
CMS Open Payments — General Payments 378 supporting records · 290 recipient NPIs · example record 1186470979 |
Reyvow · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
51 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 414 | 84 |
| Memantine Hcl | Memantine Hcl | 350 | 72 |
| Topiramate | Topiramate | 167 | 27 |
| Donepezil Hcl | Donepezil Hcl | 164 | 46 |
| Primidone | Primidone | 159 | 31 |
| Amitriptyline Hcl | Amitriptyline Hcl | 156 | 32 |
| Pregabalin | Pregabalin | 152 | 29 |
| Ubrelvy | Ubrogepant | 150 | 33 |
| Levetiracetam | Levetiracetam | 121 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 118 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 97 | 24 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 89 | 16 |
| Baclofen | Baclofen | 74 | 16 |
| Sertraline Hcl | Sertraline Hcl | 74 | 13 |
| Emgality Pen | Galcanezumab-Gnlm | 73 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 71 | 13 |
| Aimovig Autoinjector | Erenumab-Aooe | 69 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 68 | 20 |
| Topiramate Er | Topiramate | 65 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 62 | 18 |
| Propranolol Hcl | Propranolol Hcl | 52 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 51 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 51 | 12 |
| Dalfampridine Er | Dalfampridine | 50 | suppressed |
| Qulipta | Atogepant | 48 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 45 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 44 | 12 |
| Divalproex Sodium Er | Divalproex Sodium | 42 | 13 |
| Lacosamide | Lacosamide | 42 | suppressed |
| Lamotrigine | Lamotrigine | 39 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 39 | 11 |
| Oxcarbazepine | Oxcarbazepine | 32 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 31 | suppressed |
| Lorazepam | Lorazepam | 30 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 30 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 30 | suppressed |
| Alprazolam | Alprazolam | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Zonisamide | Zonisamide | 29 | suppressed |
| Teriflunomide | Teriflunomide | 28 | suppressed |
| Amantadine | Amantadine Hcl | 27 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | suppressed |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Carbamazepine | Carbamazepine | 25 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 24 | suppressed |
| Modafinil | Modafinil | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Ajovy Syringe | Fremanezumab-Vfrm | 22 | suppressed |
| Levetiracetam Er | Levetiracetam | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 21 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 19 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 13 | suppressed |
| Horizant | Gabapentin Enacarbil | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Avonex Pen (4 Pack) | Interferon Beta-1a | 12 | suppressed |
| Ingrezza | Valbenazine Tosylate | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Neupro | Rotigotine | 12 | suppressed |
| Reyvow | Lasmiditan Succinate | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 11 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 11 | suppressed |
| Bafiertam | Monomethyl Fumarate | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,541.74 · 152 records | ABBVIE INC. | AMYVID, AUSTEDO XR, BOTOX, BRIUMVI, CDS - MCT/CEM Monitoring, CREXONT, Cala kIQ, DAYBUE, Dysport, FYCOMPA, Gamunex-C, General - DBS, HORIZANT, HYQVIA, Hizentra, INGREZZA, KESIMPTA, KISUNLA, LEQEMBI, Mavenclad, Motpoly XR, NUEDEXTA, NUPLAZID, NURTEC ODT, ONPATTRO, PANZYGA, PONVORY, QULIPTA, REXULTI, Rystiggo, SKYCLARYS, Senza, Symbravo, TYSABRI, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VUMERITY, VYALEV, VYEPTI, VYVGART, WAKIX, ZAVZPRET, ZEPOSIA | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Horizant play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error